Publication date: Nov 14, 2024
This review aims to present current data on the course of COVID-19 in patients with Cushing syndrome (CS) and discuss treatment for CS during to the pandemic. Literature review using PubMed (pubmed. ncbi. nlm. nih. gov). The search included the following terms: “COVID19” in combination with “Cushing syndrome”, “Hypercortisolism” and “Glucocorticoid”. Chronic hypercortisolism has been reported to increase infectious risk and worsens prognostic of patients with COVID-19 potentially due to its direct impact on the immune system: lymphopenia, impairment of monocytes and neutrophils activity, diminution of complement activation. Main metabolic complications of CS – i. e. diabetes, hypertension and obesity – have been recognized as COVID-19 complications risk factors. Patients with CS treated with steroidogenesis inhibitors might experience adrenal insufficiency during COVID-19. Special attention should be paid to patients with CS and COVID-19. The pandemic has impacted – and delayed – care of chronic illnesses including CS. Specific recommendations had been provided during the pandemic: favor telemedicine consultations, limit in-hospital explorations and postpone surgery when feasible. There are enough evidence for an increased prevalence and severity of COVID-19 to recommend a specific attention and caution in patients with CS.
Concepts | Keywords |
---|---|
Covid19 | COVID-19 |
Diabetes | Cushing disease |
Pandemic | Physiopathology |
Steroidogenesis | Risk factors |
Surgery | SARS-CoV-2 |
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | Cushing’s syndrome |
disease | MESH | COVID-19 |
pathway | KEGG | Cushing syndrome |
pathway | REACTOME | Immune System |
disease | MESH | lymphopenia |
disease | MESH | complications |
disease | MESH | hypertension |
disease | MESH | obesity |
disease | MESH | adrenal insufficiency |
disease | MESH | chronic illnesses |
disease | MESH | Long Covid |
disease | MESH | Cushing disease |